Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects
Cancers · 26.01.2024 · 16 (3) · 544
DOI: 10.3390/cancers16030544 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.01.2024. Verfasst von Atsushi Makimoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Tokyo Metropolitan Children's Medical Center, Fuchu 183-8561, Japan. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sun Pharma Japan Co., Ltd..
Abstract (Originalsprache)
Retinoids are vitamin A derivatives and include trans-retinoic acid, isotretinoin, tamibarotene, and bexarotene, all of which are currently available for clinical use. The clinical development of retinoid therapy for neuroblastoma has a history spanning more than four decades. The most promising agent is isotretinoin, which can contribute to improving event-free survival in patients with high-risk neuroblastoma by approximately 10% when administered over six months as maintenance therapy. Although isotretinoin is regarded as an essential component in the standard clinical management of high-risk neuroblastoma, its use for this purpose in the US and EU is off-label. To promote isotretinoin use in Japan as a treatment for neuroblastoma, our clinical research team is planning to launch an investigator-initiated, registration-directed clinical trial. The present review article discusses the basic science behind retinoid therapy, pre-clinical/clinical evidence on neuroblastoma, the concept of the proposed clinical trial, and prospects for this therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Tokyo Metropolitan Children's Medical Center, Fuchu 183-8561, Japan.
- Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Fuchu 183-8561, Japan.
- Department of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Fuchu 183-8561, Japan.
- Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka 534-0021, Japan.
- Children's Cancer Center, National Center for Child Health and Development, Tokyo 157-8535, Japan.
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan.
ORCID-Profile: Atsushi Makimoto, Tomoko Iehara
Förderung
- Sun Pharma Japan Co., Ltd.
Zitieren
APA
Makimoto, A., Fujisaki, H., Matsumoto, K., Takahashi, Y., Cho, Y., Morikawa, Y., Yuza, Y., Tajiri, T., & Iehara, T. (2024). Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects. Cancers, 16(3), 544. https://doi.org/10.3390/cancers16030544
Vancouver
Makimoto A, Fujisaki H, Matsumoto K, Takahashi Y, Cho Y, Morikawa Y, et al. Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects. Cancers. 2024;16(3):544. doi:10.3390/cancers16030544
BibTeX
@article{Makimoto2024,
author = {Makimoto, Atsushi and Fujisaki, Hiroyuki and Matsumoto, Kimikazu and Takahashi, Yoshiyuki and Cho, Yuko and Morikawa, Yoshihiko and Yuza, Yuki and Tajiri, Tatsuro and Iehara, Tomoko},
title = {Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects},
journal = {Cancers},
year = {2024},
volume = {16},
number = {3},
pages = {544},
doi = {10.3390/cancers16030544}
}
EUVIMED